2024
Spatial Engineering of Heterotypic Antigens on a DNA Framework for the Preparation of Mosaic Nanoparticle Vaccines with Enhanced Immune Activation against SARS‐CoV‐2 Variants
Zhang J, Xu Y, Chen M, Wang S, Lin G, Huang Y, Yang C, Yang Y, Song Y. Spatial Engineering of Heterotypic Antigens on a DNA Framework for the Preparation of Mosaic Nanoparticle Vaccines with Enhanced Immune Activation against SARS‐CoV‐2 Variants. Angewandte Chemie International Edition 2024, 63: e202412294. PMID: 39030890, DOI: 10.1002/anie.202412294.Peer-Reviewed Original ResearchNanoparticle vaccineReceptor-binding domainHeterotypic antigensBroad-spectrum neutralizing antibodiesSARS-CoV-2 spike trimerVaccine-induced immunityNanotechnology-based strategiesEnhanced immune activationOmicron receptor-binding domainMosaic vaccinesImmune activationSystematic in vitroNeutralizing antibodiesSARS-CoV-2 variantsMosaic nanoparticlesImmunological investigationsExcessive inflammationAntigen distributionAntigenSpike trimerRBD antigenSARS-CoV-2DNAVaccineAntiviral capabilitiesSpatial Engineering of Heterotypic Antigens on a DNA Framework for the Preparation of Mosaic Nanoparticle Vaccines with Enhanced Immune Activation against SARS‐CoV‐2 Variants
Zhang J, Xu Y, Chen M, Wang S, Lin G, Huang Y, Yang C, Yang Y, Song Y. Spatial Engineering of Heterotypic Antigens on a DNA Framework for the Preparation of Mosaic Nanoparticle Vaccines with Enhanced Immune Activation against SARS‐CoV‐2 Variants. Angewandte Chemie 2024, 136 DOI: 10.1002/ange.202412294.Peer-Reviewed Original ResearchNanoparticle vaccineReceptor-binding domainHeterotypic antigensBroad-spectrum neutralizing antibodiesSARS-CoV-2 spike trimerVaccine-induced immunityNanotechnology-based strategiesEnhanced immune activationOmicron receptor-binding domainMosaic vaccinesImmune activationSystematic in vitroNeutralizing antibodiesSARS-CoV-2 variantsMosaic nanoparticlesImmunological investigationsExcessive inflammationAntigen distributionAntigenSpike trimerRBD antigenSARS-CoV-2DNAVaccineAntiviral capabilities
2023
Author Correction: A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
Weidenbacher P, Sanyal M, Friedland N, Tang S, Arunachalam P, Hu M, Kumru O, Morris M, Fontenot J, Shirreff L, Do J, Cheng Y, Vasudevan G, Feinberg M, Villinger F, Hanson C, Joshi S, Volkin D, Pulendran B, Kim P. Author Correction: A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates. Nature Communications 2023, 14: 6211. PMID: 37798288, PMCID: PMC10556009, DOI: 10.1038/s41467-023-42061-4.Peer-Reviewed Original ResearchDevelopment of an mRNA-lipid nanoparticle vaccine against Lyme disease
Pine M, Arora G, Hart T, Bettini E, Gaudette B, Muramatsu H, Tombácz I, Kambayashi T, Tam Y, Brisson D, Allman D, Locci M, Weissman D, Fikrig E, Pardi N. Development of an mRNA-lipid nanoparticle vaccine against Lyme disease. Molecular Therapy 2023, 31: 2702-2714. PMID: 37533256, PMCID: PMC10492027, DOI: 10.1016/j.ymthe.2023.07.022.Peer-Reviewed Original ResearchConceptsLyme diseaseImmune responseCell-mediated immune responsesLyme disease vaccinePotent immune responsesProtein subunit vaccinesSARS-CoV-2Surface protein AVector-borne infectious diseasesMRNA-LNP vaccineOuter surface protein ASingle immunizationProtective efficacyMRNA vaccinesClinical vaccinesDisease vaccineNanoparticle vaccineSubunit vaccineVaccine developmentVaccineBacterial infectionsMRNA-LNPInfectious diseasesDiseaseMRNA platformA ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
Weidenbacher P, Sanyal M, Friedland N, Tang S, Arunachalam P, Hu M, Kumru O, Morris M, Fontenot J, Shirreff L, Do J, Cheng Y, Vasudevan G, Feinberg M, Villinger F, Hanson C, Joshi S, Volkin D, Pulendran B, Kim P. A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates. Nature Communications 2023, 14: 2149. PMID: 37069151, PMCID: PMC10110616, DOI: 10.1038/s41467-023-37417-9.Peer-Reviewed Original ResearchConceptsNeutralizing antiseraLonger-lasting immunityNon-human primatesFerritin-basedOnce-yearlyNanoparticle vaccineSARS-CoV-2 variantsOmicron BQVaccine dosePediatric useAnamnestic responseInitial immunizationVaccine candidatesSARS-CoV-2Development of COVID-19 vaccinesCell linesCOVID-19 vaccineVaccineSARS-CoV-1Cell culturesImmunity
2022
Simplified Purification of Glycoprotein-Modified Ferritin Nanoparticles for Vaccine Development
Weidenbacher P, Musunuri S, Powell A, Tang S, Do J, Sanyal M, Kim P. Simplified Purification of Glycoprotein-Modified Ferritin Nanoparticles for Vaccine Development. Biochemistry 2022, 62: 292-299. PMID: 35960597, PMCID: PMC9850919, DOI: 10.1021/acs.biochem.2c00241.Peer-Reviewed Original Research
2020
Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells
Baharom F, Ramirez-Valdez RA, Tobin KKS, Yamane H, Dutertre CA, Khalilnezhad A, Reynoso GV, Coble VL, Lynn GM, Mulè MP, Martins AJ, Finnigan JP, Zhang XM, Hamerman JA, Bhardwaj N, Tsang JS, Hickman HD, Ginhoux F, Ishizuka AS, Seder RA. Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells. Nature Immunology 2020, 22: 41-52. PMID: 33139915, PMCID: PMC7746638, DOI: 10.1038/s41590-020-00810-3.Peer-Reviewed Original ResearchConceptsNeoantigen-specific CD8T cellsToll-like receptor 7/8 agonistQuality of CD8Stem-like TCF1T cell immunityStem-like CD8Superior antitumor responsesPersonalized cancer vaccinesStem-like genesStem-like cellsIntravenous vaccinationNanoparticle vaccinationAntitumor immunityCheckpoint blockadeCell immunityDendritic cellsAntitumor responseEffector cellsSubcutaneous immunizationCancer vaccinesVaccine parametersNeoantigen peptidesAntigen presentationNanoparticle vaccine
2008
Design opportunities for actively targeted nanoparticle vaccines
Fahmy TM, Demento SL, Caplan MJ, Mellman I, Saltzman WM. Design opportunities for actively targeted nanoparticle vaccines. Nanomedicine 2008, 3: 343-355. PMID: 18510429, PMCID: PMC5545123, DOI: 10.2217/17435889.3.3.343.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply